June 2017
Volume 58, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2017
Ocriplasmin for the treatment of vitreomacular traction with or without macular hole – predictors of success
Author Affiliations & Notes
  • Janine Lenk
    Ophthalmology, University of Dresden, Dresden, Germany
  • Egbert Matthé
    Ophthalmology, University of Dresden, Dresden, Germany
  • Lutz E Pillunat
    Ophthalmology, University of Dresden, Dresden, Germany
  • Dirk Sandner
    Ophthalmology, University of Dresden, Dresden, Germany
  • Footnotes
    Commercial Relationships   Janine Lenk, None; Egbert Matthé, None; Lutz Pillunat, None; Dirk Sandner, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2017, Vol.58, 3696. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Janine Lenk, Egbert Matthé, Lutz E Pillunat, Dirk Sandner; Ocriplasmin for the treatment of vitreomacular traction with or without macular hole – predictors of success. Invest. Ophthalmol. Vis. Sci. 2017;58(8):3696.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Vitreomacular traction (VMT) means an abnormal adhesion between vitreous cortex and retina, especially in the fovea, which might even result in macular holes. In symptomatic cases patients mainly complain about metamorphopsias and decreased visual acuity. Since 2013,
Ocriplasmin (Jetrea®) has been approved for treatment of symptomatic vitreomacular traction with or without macular holes (≤ 400 µm).

Methods : We retrospectively examined 23 eyes of 21 patients who underwent intravitreal ocriplasmin treatment for symptomatic vitreomacular traction with or without macular holes. Best corrected visual acuity (BCVA) and central retinal thickness (CRT) were measured before and after treatment. We investigated the different morphologic appearance of VMT. Statistical analysis was performed using SPSS: t-test for paired samples was used. Multivariate Regression was used in order to investigate predictors for successful resolution (age, lense status, gender, size of VMT).

Results : Vitreomacular traction was resolved in 8 out of 23 eyes (34,8%). 2 out of 4 macular holes closed during treatment. The average BCVA was 0.39 ± 0.25 logMAR at baseline and 0,41 ± 0,24 logMAR at the first follow-up visit after injection (P=0,613). The average CRT was 453,3 ± 172,7 µm at baseline and decreased slightly to 412,0 ± 212 µm (P=0.124). Regarding predictors for successful VMT-resolution, younger patients were more likely to have complete resolution of vitreomacular traction than older patients (P= 0.05). Furthermore, patients who reported chromatopsia had more VMT resolution than did those without. A high dome-shape morphology of VMT seems to be a disadvantage compared to a flat, punctuated adhesion.

Conclusions : Intravitreal injection of Ocriplasmin seems to be a useful tool in patients with symtomatic vitreomacular traction. A critical patient selection is important to raise chances for successful treatment.

This is an abstract that was submitted for the 2017 ARVO Annual Meeting, held in Baltimore, MD, May 7-11, 2017.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×